Science Advances

SEP 4, 2026 · JOURNAL ARTICLE

Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity

Science Advances

Preclinical study in animal models and ex vivo human cells demonstrating mechanism and tolerability of a novel IL-2 variant; supports rationale for clinical evaluation but lacks human efficacy data.

SEP 4, 2026 · JOURNAL ARTICLE

Supramolecular immunomodulatory hydrogelator potentiates CAR-T therapy with long-lasting endogenous immunity toward solid tumor eradication

Science Advances

Preclinical mechanistic study in murine tumor models demonstrating a novel hydrogel delivery platform; no human data, clinical outcomes, or comparative efficacy data reported.

AUG 21, 2026 · JOURNAL ARTICLE

RNA delivery to the corneal endothelium using charge-altering releasable transporters

Science Advances

Early-phase, uncontrolled mechanistic work demonstrating proof-of-concept for a novel delivery platform in mouse models, human cells in vitro, and one non-human primate, without efficacy endpoints or clinical outcome data.

AUG 12, 2026 · JOURNAL ARTICLE

Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy

Science Advances

Proteogenomic characterization study identifying molecular subtypes and proposing IL-33 as a therapeutic target, with preclinical validation in animal models but no clinical efficacy data in patients.